Heat Biologics Inc (HTBX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Heat Biologics Inc (Heat Biologics) is a biopharmaceutical company which develops novel immuno therapeutics for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory antibodies targeted at hematologic malignancies, and other tumors. The co-stimulatory antibodies harness human body's natural antigen specific immune response to reprogram the immune system to offer durable clinical outcomes. Heat Biologics’ off-the-shelf therapies are based on its proprietary T-cell activating platform (TCAP), which turns immunologically cold tumors hot. It has subsidiaries in the US, Germany, and Australia. Heat Biologics is headquartered in Durham, North Carolina, the US.
Heat Biologics Inc Key Recent Developments
Feb 28,2018: Heat Biologics Reports Fiscal Year 2017 Financial Results
Feb 28,2018: Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards
Nov 13,2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update
Nov 11,2017: Heat Biologics Presents Follow-up Data on its ComPACT T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 06,2017: Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting